Most Read Articles
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Ambrisentan–tadalafil combo effective against connective tissue disease-related PAH

10 Apr 2020

Combination therapy with ambrisentan plus tadalafil provides greater benefits than either agent alone in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), especially those with typical PAH haemodynamic characteristics at baseline, according to a posthoc analysis of the AMBITION* study.

The analysis included 216 CTD-PAH patients, among whom 117 had received the combination regimen and 99 monotherapy with either ambrisentan or tadalafil. Of the patients, 81 and 56 had systemic sclerosis (SSc)-PAH, respectively. Researchers assessed time to clinical failure (TtCF) by baseline characteristics, treatment assignment and risk group (low, intermediate and high) at baseline and week 16.

The risk of clinical failure was lower with the combination than with monotherapy both in CTD-PAH (risk reduction, 51.7 percent; hazard ratio [HR], 0.483, 95 percent confidence interval [CI], 0.286–0.817) and in SSc-PAH (risk reduction, 53.7 percent; HR, 0.463, 95 percent CI, 0.240–0.895).

The effect was most prominent in the group of patients with haemodynamic parameters characteristic of typical PAH without features of left heart disease and/or restrictive lung disease at baseline.

Results were consistent in the baseline low-risk patient group (HR not calculated due to no events in the combination arm), baseline intermediate-risk group (HR, 0.519, 95 percent CI, 0.297–0.905) and in the week-16 low-risk group (HR, 0.069, 95 percent CI, 0.009–0.548).

Based on the present data, incorporating additional haemodynamic information should improve risk stratification validity at follow-up, the researchers said. Additional investigation is warranted to determine the optimal predictive tools in terms of applicability and accuracy at baseline, and follow-up in a large-scale cohort.

*Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.